Recombinant hyaluronidase
Showing 1 - 25 of 2,374
Health, Subjective Trial in Seoul (BMI2004, 0.9% NaCl)
Completed
- Health, Subjective
- BMI2004
- 0.9% NaCl
-
Seoul, Heukseok-ro, Dongjak-gu, Korea, Republic ofChung-Ang University Hospital
Jun 26, 2023
HIV Trial in Las Vegas (Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20))
Recruiting
- HIV Infections
- Cabotegravir 200 mg/mL
- +2 more
-
Orlando, Florida
- +3 more
Dec 1, 2022
Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- HYQVIA
- (no location specified)
Feb 23, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC
Active, not recruiting
- Multiple Myeloma
- Daratumumab Subcutaneous (SC) Administration
- Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
-
Atlanta, Georgia
- +11 more
Aug 11, 2022
HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)
Completed
- HIV Antibodies
- VRC-HIVMAB091-00-AB
- EDP
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 8, 2022
Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life
Not yet recruiting
- Plasma Cell Myeloma
- Daratumumab and Hyaluronidase-fihj
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8 Trial in Los Angeles (Atezolizumab
Recruiting
- Lung Non-Small Cell Carcinoma
- +10 more
- Atezolizumab and Recombinant Human Hyaluronidase
- Survey Administration
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Jan 31, 2023
Outcomes Study (FIGARO)
Completed
- Primary Immunodeficiency
- Secondary Immune Deficiency
- HyQvia
-
Paris, France
- +3 more
Mar 18, 2022
Primary Immunodeficiency Diseases (PID) Trial (TAK-881)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- (no location specified)
Oct 4, 2023
Healthy Volunteers Trial in Hialeah (TAK-881)
Completed
- Healthy Volunteers
- TAK-881
-
Hialeah, FloridaClinical Pharmacology of Miami
Apr 28, 2022
Primary Immunodeficiency Diseases (PID) Trial in Centennial, North Palm Beach, Dallas (Recombinant human hyaluronidase + immune
Completed
- Primary Immunodeficiency Diseases (PID)
- Recombinant human hyaluronidase + immune globulin intravenous
-
Centennial, Colorado
- +2 more
Apr 30, 2021
Hereditary Angioedema Trial in United States (CINRYZE with rHuPH20)
Completed
- Hereditary Angioedema
- CINRYZE with rHuPH20
-
Scottsdale, Arizona
- +3 more
Jun 16, 2021
Primary Immunodeficiency Diseases (PID) Trial (TAK-771)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- (no location specified)
Aug 22, 2022
HIV Trial in Austin (VH3810109, rHuPH20)
Recruiting
- HIV Infections
- VH3810109
- rHuPH20
-
Austin, TexasGSK Investigational Site
Sep 19, 2022
Hereditary Angioedema (HAE) Trial in Worldwide (CINRYZE with rHuPH20)
Completed
- Hereditary Angioedema (HAE)
- CINRYZE with rHuPH20
-
Birmingham, Alabama
- +22 more
May 11, 2021
Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Recombinant human hyaluronidase (rHuPH20)+ immune
Completed
- Primary Immunodeficiency Diseases (PID)
- Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
-
Cypress, California
- +13 more
Apr 30, 2021
Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Infusion (Human), 10%, Recombinant human
Completed
- Primary Immunodeficiency Diseases (PID)
- Immune Globulin Infusion (Human), 10%
- Recombinant human hyaluronidase
-
Irvine, California
- +9 more
Apr 30, 2021
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) Trial in Japan (TAK-771)
Recruiting
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Multifocal Motor Neuropathy (MMN)
-
Nagoya, Aichi, Japan
- +16 more
Feb 2, 2023
HIV Trial in New Zealand, United States (Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL)
Recruiting
- HIV Infections
- Cabotegravir sodium (Oral Lead In)
- +6 more
-
Orlando, Florida
- +4 more
Mar 29, 2022